Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6138278 | Trends in Parasitology | 2008 | 4 Pages |
Abstract
Intermittent preventive treatment is the prescheduled administration of antimalarial drugs to at-risk patients in endemic areas. This approach, which is recommended for pregnant women, is being evaluated in children. Sulfadoxine-pyrimethamine plus amodiaquine recently proved to be more protective than artemisinin-containing regimens. Therefore, the use of artemisinin derivatives could potentially be restricted to symptomatic patients. Determinants of three pending issues: safety, efficacy throughout childhood, and effectiveness - the latter depending on the implementation of sustainable delivery mechanisms - are analyzed in this comment.
Related Topics
Life Sciences
Immunology and Microbiology
Parasitology
Authors
Pierre A. Buffet, Valérie Briand, Laurent Rénia, Marc Thellier, Martin Danis, Dominique Mazier,